Compare Stocks: KLRA, APGE, IMVT, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.37	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
IMVT Immunovant	$37.98 -2.0%	$40.49	$14.58 ▼ $45.42	$7.85B	0.81	1.50 million shs	134,805 shs
KLRA Kailera Therapeutics	$14.69 -1.0%	$18.20	$14.51 ▼ $28.23	$1.90B	N/A	724,717 shs	103,624 shs
SYRE Spyre Therapeutics	$87.63 +0.8%	$98.03	$14.51 ▼ $110.18	$7.70B	2.99	1.08 million shs	136,955 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.31%	+50.92%	+251.20%
IMVT Immunovant	-2.07%	-1.87%	-2.86%	+17.85%	+136.28%
KLRA Kailera Therapeutics	-9.68%	-6.37%	-21.81%	-24.05%	+1,483,999,900.00%
SYRE Spyre Therapeutics	-4.25%	-0.14%	-17.47%	+7.63%	+419.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.37	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
IMVT Immunovant	$37.98 -2.0%	$40.49	$14.58 ▼ $45.42	$7.85B	0.81	1.50 million shs	134,805 shs
KLRA Kailera Therapeutics	$14.69 -1.0%	$18.20	$14.51 ▼ $28.23	$1.90B	N/A	724,717 shs	103,624 shs
SYRE Spyre Therapeutics	$87.63 +0.8%	$98.03	$14.51 ▼ $110.18	$7.70B	2.99	1.08 million shs	136,955 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.31%	+50.92%	+251.20%
IMVT Immunovant	-2.07%	-1.87%	-2.86%	+17.85%	+136.28%
KLRA Kailera Therapeutics	-9.68%	-6.37%	-21.81%	-24.05%	+1,483,999,900.00%
SYRE Spyre Therapeutics	-4.25%	-0.14%	-17.47%	+7.63%	+419.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
IMVT Immunovant	2.55	Moderate Buy	$44.00	15.85% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	191.01% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	25.17% Upside

Current Analyst Ratings Breakdown

Latest KLRA, APGE, IMVT, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
9/1/2026	SYRE Spyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/25/2026	IMVT Immunovant	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/11/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$112.00 ➝ $132.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	$890K	8,658.83	N/A	N/A	$7.21 per share	12.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest KLRA, APGE, IMVT, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
IMVT Immunovant	N/A	7.27	7.27
KLRA Kailera Therapeutics	N/A	11.11	11.11
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IMVT Immunovant	47.08%
KLRA Kailera Therapeutics	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
IMVT Immunovant	1.90%
KLRA Kailera Therapeutics	N/A
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

KLRA, APGE, IMVT, and SYRE Headlines

Recent News About These Companies

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10 at 5:27 AM | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10 at 3:03 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research

September 10 at 1:24 AM | americanbankingnews.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9 at 3:00 PM | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9 at 1:58 PM | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9 at 11:01 AM | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9 at 8:29 AM | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9 at 5:51 AM | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8 at 12:55 PM | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8 at 12:55 PM | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8 at 12:55 PM | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8 at 11:41 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened

September 8 at 11:19 AM | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 8 at 8:00 AM | globenewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

September 4, 2026 | globenewswire.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of Stock

September 4, 2026 | insidertrades.com